Karen Cheng

Patient Advocate International Myositis Society

Karen is a global healthcare executive with a passion for advancing patient care in rare diseases. With a medical background and international experience in medical affairs, clinical development, patient engagement, and commercialisation of medical devices and pharmaceuticals, she has led international product launches and cross-functional initiatives across multiple disease areas. Karen’s work in the industry is inspired by her unique journey as a rare disease patient, which fuels her dedication and deep commitment to advancing patient care and outcomes through innovation, advocacy, education and global health strategies.

Pharma Launch Excellence Summit Main Conference Day 1: Wednesday 2nd December

2:00 PM Panel Discussion: Leveraging Medical Affairs to Build Evidence, Engage Stakeholders, & Accelerate Launch Success

Medical affairs has evolved from a launch support function into a key driver of launch success. With long-term launch performance often determined within the first six months post-launch, medical affairs teams can be utilised to gather evidence early, effectively engage stakeholders and ensure that appropriate healthcare systems are ready to adopt a new product at launch.

• Learning why engaging the medical affairs function 48–60 months before launch is critical to drive launch success

• Hearing how to effectively leverage medical affairs teams to lead evidence generation when preparing for launch execution

• Using the medical affairs function to prepare healthcare systems for rapid adoption of therapies at launch: What steps can you take?

Pharma Launch Excellence Summit Pre-Conference Focus Day: Launch Excellence in Rare Disease: Tuesday 1st December

10:40 AM Panel Discussion: Partnering with Patient Advocacy Groups in Drug Development to Accelerate Rare Disease Launch Success

Patient advocacy groups can play a pivotal role in the successful development and launch of rare disease therapies. Early collaboration with patient advocacy groups can be a critical determinant of launch success. How can launch excellence teams ensure patient perspectives are meaningfully embedded throughout the drug development lifecycle?

• Building strong relationships with patients, caregivers, patient advocacy groups and external experts to maximise the success of your rare disease therapy launch

• Leveraging patient advocacy group partnerships to gain critical insights, engage diverse patient populations and support market access efforts to ensure your therapy successfully reaches patients who need it most

• Discovering how successful rare disease launches benefited from strong collaboration with patient advocacy groups to apply lessons learned to your next launch

Check out the incredible speaker line-up to see who will be joining Karen.

Download The Latest Agenda

In Partnership With:

QUESTIONS?

Address: IQPC Ltd, 129 Wilton Road,
London SW1V 1JZ
Telephone: 44 (0) 207 368 9300
Fax: 44 (0) 207 368 9301
Email: enquire@iqpc.co.uk